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Abstract 
Case report and literature review on AML with 
t(7;21)(p22;q22) and 5q abnormality. 
Clinics 
Age and sex 
57 years old female patient. 
Previous history 
No preleukemia, no previous malignancy, no inborn 
condition of note, no main items.  
Organomegaly 
No hepatomegaly, no splenomegaly, no enlarged 
lymph nodes, no central nervous system 
involvement.  
Blood 
WBC: 2.32 X 109/l 
HB: 6.9g/dl 
Platelets: 170X 109/l 
Blasts: 0% 
Bone marrow: 25% 
Cyto-Pathology 
Classification 
Immunophenotype 
CD10 (partial), CD11b (partial), CD13, CD14 
(partial), CD15 (partial), CD16 (partial), CD22 
(partial), CD34 (partial), CD36 (partial), CD38, 
CD56 (partial), CD64 (partial), CD117 (partial), 
HLA-DR (bright), icCD22 (partial), and MPO 
(partial) with aberrant expression of CD7 (partial). 
Rearranged Ig Tcr 
Not performed. 
Pathology 
Acute myeloid leukemia, not otherwise specified 
(AML, NOS), with monocytic differentiation. 
Electron microscopy 
Not performed. 
Diagnosis 
Acute myeloid leukemia, not otherwise specified 
(AML, NOS); Acute myelomonocytic leukemia 
subtype. 
Survival 
Date of diagnosis: 02-2013 
Treatment 
Following diagnosis, the patient was seen at an 
outside institution for treatment and was placed on 
Revlimid therapy as opposed to induction 
chemotherapy for about 5 months without 
improvement or significant deterioration of her 
blood counts. She was referred to our institution to 
be evaluated for allogenic stem-cell transplantation. 
A repeat bone marrow biopsy (~6-7 months post 
diagnosis) confirmed persistent AML, and the 
cytogenetic studies were performed. The patient 
was then started on 7+3 AML induction 
(Cytarabine 320 mg IV continuous days 1-7, 
Idarubicin 19 mg IV on days 3-6). A day 16 repeat 
bone marrow biopsy showed persistent presence of 
abnormal myeloblasts. Biopsy about 6 weeks 
following induction therapy showed remission with 
no excess or abnormal myeloblasts. She was 
subsequently admitted and completed her first cycle 
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of consolidation chemotherapy with high-dose 
cytarabine (3 gm/m2 IV q 12 hours on days 1, 3, 5 
for 6 doses). 
Complete remission was obtained.  
Treatment related death: no  
Relapse: no.  
Status: Alive. Last follow up: 12-2013. 
Survival: 9 months 
Karyotype 
Sample: Bone marrow aspirate 
Culture time: 24h without stimulating agents 
Banding: GPG 
Results 
Analysis of 20 metaphase cells revealed an 
abnormal female karyotype with additional material 
of unknown origin at 5q13 leading to partial 
deletion of 5q in 5/20 metaphase cells examined. 
The karyotype was described as: 
46,XX,add(5)(q13)[5]/46,XX[15]. 
Other molecular cytogenetics technics 
Fluorescence in situ hybridization (FISH) using the 
LSI RUNX1(AML1)/RUNXT1(ETO) Dual Color 
Translocation Probe and LSI EGR1/D5S23, 
D5S721 Dual Color Probe Set (Abbott Molecular, 
USA) were performed. 
Other molecular cytogenetics results 
Split of the RUNX1 gene was detected in the  
interphase nuclei (three green signals) in 235/300 
nuclei, and 5q deletion was detected (two green one 
orange signal pattern) in 19/300 nuclei.  
Subsequent metaphase FISH on previously G-
banded slides was performed by using 
RUNX1/RUNXT1 and 7p sub-telomere probe.  
The cryptic translocation t(7;21) was identified.  
Based on the metaphase FISH study, the final ISCN 
was characterized as: 
46,XX,add(5)(q13)[5]/46,XX[15].ish 
t(7;21)(p22;q22)(RUNX1+; VIJyRM2185+)[2]. 
Other Molecular Studies 
Technics: 
DNA was isolated by routine methods and 
subjected to quantitative real-time polymerase chain 
reaction using allele-specific primers 
complementary to the mutated and wild-type 
sequences of the JAK2 gene. 
Results: 
Negative for JAK2 mutation V617F. 
Other Findings 
Note: 
The previous FISH studies on G-banded 
metaphases showed that the AML1 signal was split 
and moved to 7p, and the subtelomeric probes for 
7p/q showed that the 7p signal moved to 21q, thus, 
establishing the t(7;12). 
 
Interphase FISH with three signals of RUNX1 (green) and two signals of RUNXT1 (orange). 
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Interphase FISH with two signals of 5p15.2 region (green) and one signal of EGR1 (orange) suggests loss of 5q. 
 
 
 
 
 
 
Karyotype on the bone marrow aspirate showing additional material of unknown origin attached at 5q13 leading to 5q loss. 
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The sequential FISH study on a previously G-banded metaphase with LSI RUNX1/RUNXT1 probe showing the green signals of 
RUNX1 on der(7), der(21) and normal chromosome 21, respectively. Two normal orange of RUNXT1 are seen on the 
chromosomes 8. 
 
 
 
 
FISH with TelVysion 7p (green, on the sub-telomere region of 7p), 7q (orange, on the sub-telomere region of 7q) and 
chromosome 14 (yellow and aqua) showing one green signal of 7p on der(21), and the der(7) is missing a green signal. Two 
normal chromosomes 14 are seen as indicated by the signal pattern (one yellow and one aqua signals on two normal 
chromosomes 14 respectively). 
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Comments 
We present a new case of AML, NOS with 
monocytic differentiation (myelomonocytic 
leukemia) which was shown to carry a cryptic 
t(7;21)(p22;q22) and 5q loss.  
The cryptic translocation t(7;21)(p22;q22) 
involving RUNX1 and presumably USP42 is a rare 
recurrent abnormality in AML (Paulsson et al., 
2006) and shows association with 5q abnormalities. 
RUNX1 codes for a transcription factor in the 'Runt 
domain' gene family and is a regulator of 
hematopoiesis.  
The gene USP42 is involved in the ubiquitin 
pathway, and is fused to the 3' region of the 
RUNX1 gene in this translocation.  
A recent study evaluated 397 consecutive AML 
patients with RUNX1 FISH probes and identified 3 
patients with t(7;21)(p22;q22), suggesting a relative 
incidence in about 1% of AML cases (Jeandidier et 
al., 2012).  
Nine previously reported cases have been identified 
on literature review (see references below) with a 
broad age of onset (7-68 years, median 39), many 
with monocytic differentiation, frequently aberrant 
immunophenotypic antigen expression (often with 
CD7 and/or CD56), and generally poor response to 
induction chemotherapy.  
Long term survival data are limited at present. 
Our presented case also had evidence of persistent 
leukemia after 6 months of initial treatment with 
Revlimid (at another institution), but achieved 
complete remission by morphology, flow, and 
cytogenetics after standard 7+3 AML induction 
chemotherapy.  
She has since completed her first cycle of 
consolidation chemotherapy (high-dose Cytarabine) 
without incident. She is alive and in remission as of 
9 months from diagnosis. 
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